These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2984980)

  • 1. Controlled trial of enviroxime against natural rhinovirus infections in a community.
    Miller FD; Monto AS; DeLong DC; Exelby A; Bryan ER; Srivastava S
    Antimicrob Agents Chemother; 1985 Jan; 27(1):102-6. PubMed ID: 2984980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical enviroxime against rhinovirus infection.
    Levandowski RA; Pachucki CT; Rubenis M; Jackson GG
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1004-7. PubMed ID: 6297380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic activity of enviroxime against rhinovirus infection in volunteers.
    Phillpotts RJ; Wallace J; Tyrrell DA; Tagart VB
    Antimicrob Agents Chemother; 1983 May; 23(5):671-5. PubMed ID: 6870216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection.
    Hayden FG; Gwaltney JM
    Antimicrob Agents Chemother; 1982 Jun; 21(6):892-7. PubMed ID: 6287928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of enviroxime against rhinovirus infection in man.
    Phillpotts RJ; Jones RW; Delong DC; Reed SE; Wallace J; Tyrrell DA
    Lancet; 1981 Jun; 1(8234):1342-4. PubMed ID: 6113314
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers.
    Higgins PG; Barrow GI; al-Nakib W; Tyrrell DA; DeLong DC; Lenox-Smith I
    Antiviral Res; 1988 Nov; 10(1-3):141-9. PubMed ID: 3232968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.
    Wyde PR; Six HR; Wilson SZ; Gilbert BE; Knight V
    Antimicrob Agents Chemother; 1988 Jun; 32(6):890-5. PubMed ID: 2843086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of intranasally administered 4', 6-dichloroflavan to protect against rhinovirus infection in man.
    Al-Nakib W; Willman J; Higgins PG; Tyrrell DA; Shepherd WM; Freestone DS
    Arch Virol; 1987; 92(3-4):255-60. PubMed ID: 3545152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).
    al-Nakib W; Higgins PG; Barrow GI; Tyrrell DA; Andries K; Vanden Bussche G; Taylor N; Janssen PA
    Antimicrob Agents Chemother; 1989 Apr; 33(4):522-5. PubMed ID: 2543283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coming drugs against the common cold?
    Hahn FE
    Naturwissenschaften; 1979 Aug; 66(8):417-8. PubMed ID: 228206
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chemoprophylaxis and chemotherapy of common colds caused by rhinoviruses: overview and outlook].
    Werner GH
    Bull Acad Natl Med; 1992 May; 176(5):669-81. PubMed ID: 1330221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
    Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
    J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.
    Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ; Zalman LS
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3907-16. PubMed ID: 14638501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.
    Farr BM; Gwaltney JM; Adams KF; Hayden FG
    Antimicrob Agents Chemother; 1984 Jul; 26(1):31-4. PubMed ID: 6089652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal pirodavir (R77,975) treatment of rhinovirus colds.
    Hayden FG; Hipskind GJ; Woerner DH; Eisen GF; Janssens M; Janssen PA; Andries K
    Antimicrob Agents Chemother; 1995 Feb; 39(2):290-4. PubMed ID: 7726484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on the nasal mucosa of upper respiratory viruses (common cold).
    Winther B
    Dan Med Bull; 1994 Apr; 41(2):193-204. PubMed ID: 8039434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man.
    Phillpotts RJ; Wallace J; Tyrrell DA; Freestone DS; Shepherd WM
    Arch Virol; 1983; 75(1-2):115-21. PubMed ID: 6338868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purified interferon as protection against rhinovirus infection.
    Scott GM; Phillpotts RJ; Wallace J; Secher DS; Cantell K; Tyrrell DA
    Br Med J (Clin Res Ed); 1982 Jun; 284(6332):1822-5. PubMed ID: 6177374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families.
    Monto AS; Schwartz SA; Albrecht JK
    Antimicrob Agents Chemother; 1989 Mar; 33(3):387-90. PubMed ID: 2543280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.
    Hayden FG; Kaiser DL; Albrecht JK
    Antimicrob Agents Chemother; 1988 Feb; 32(2):224-30. PubMed ID: 2834996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.